Drug Combo Could Benefit HER2-Positive Breast Cancer Cases
American Association for Cancer Research
The HER2CLIMB-02 trial reveals significant benefits, especially for breast cancer patients with brain metastases
Clinical Trials
World-First Human Trial Offers New Type 1 Diabetes Treatment
St Vincent’s Institute of Medical Research
A commonly prescribed rheumatoid arthritis drug may suppress the progression of type 1 diabetes
The COMCID Study Raises New Questions in Dementia Research
National Cerebral and Cardiovascular Center
The COMCID study is Japan’s first multicenter investigator-initiated clinical trial involving patients with mild cognitive impairment
First Two Children Receive New Gene Therapy for Rett Syndrome
Neurogene Inc.
Phase 1/2 trial showed the safety and therapeutic potential of administering a novel transgene
First WHO Clinical Trials Forum Prioritizes Sustainable Research Infrastructure
World Health Organization
Clinical trials in primary health care and hospital settings were a special focus of the forum
FDA Approves First Drug Therapy for Desmoid Tumors
U.S. Food and Drug Administration
The FDA granted the approval of Ogsiveo to SpringWorks Therapeutics Inc.
Combination Therapy Improves Rare Brain Tumors in Children
Great Ormond Street Hospital
Trials showed the effect of combination therapy on survival and quality of life in children with low- and high-grade gliomas
New Approach to Using Immunotherapy Combinations in Bladder Cancer
Netherlands Cancer Institute
Nivolumab and gemcitabine–cisplatin combo showed significantly better outcomes than standard-of-care in patients with advanced urothelial carcinoma
RNA Expression Scores Predict Response to Bladder Cancer Therapy
SWOG Cancer Research Network
Prospective trials may help assess whether molecular subtype-directed approach can improve response to neoadjuvant therapy in MIBC patients
Combo Immunotherapy Trial for Glioblastoma Commences
University of North Carolina School of Medicine
New Drug for Relapsed Blood Cancer in First Human Trial
The James Cancer Hospital and Solove Research Institute (OSUCCC – James)
CLL makes up a quarter of leukemia cases among adults and NHL accounts for 4 percent of all cancers in the US
Novel Drug Improves Rare Kidney Disorder in Phase 3 Trial
University of Minnesota Medical School
Some 42 percent of patients treated with sparsentan showed reduced proteinuria
Antibody-Drug Conjugate Benefits HER2-Low Breast Cancers
German Institute for Quality and Efficiency in Health Care (IQWiG)
Patients with HER2-low breast cancers were included in the clinical trial proving the efficacy of trastuzumab deruxtecan monotherapy
Treatment Combo Outperforms Standard-of-Care in Colorectal Cancer Trial
City of Hope
The novel therapeutic could provide a new option for patients with treatment-resistant KRAS gene mutation-positive colorectal cancer
FDA Approves Steroid-Like Drug for Duchenne Muscular Dystrophy
Children's National Hospital
Vamorolone offers a new treatment option with fewer side effects
Encaleret Restores Parathyroid Function in ADH1 Trial
Swathi Kodaikal, MSc
Some 3.9 in 100,000 people in the US are affected by ADH1, a major cause of nonsurgical hypoparathyroidism
Neoadjuvant Shows Positive Response in Advanced Melanoma Trial
SWOG Cancer Research Network
Single-agent immunotherapy shrinks over half of advanced melanomas when given before surgery
Liver Cancer Adjuvant Immunotherapy Improved Survival in Phase 3 Trial
National Cancer Centre Singapore
Some 70–90 percent of patients with hepatocellular carcinoma experience cancer recurrence after curative treatment
Perioperative Immunotherapy Significantly Improves NSCLC Outcomes
University of Texas MD Anderson Cancer Center
Results showed a 32 percent lower chance of cancer recurrence, progression, or death with immunotherapy plus chemotherapy versus chemotherapy alone
Bispecific Cancer Drug Performs Well in Early Clinical Trial
University of Pittsburgh
Tebotelimab targets two proteins on tumor cells and drives specific immune response safely and effectively